Nanoligent has been selected to showcase at the pitch elevator session at the Bioengineering and Medtech against Cancer short course on the 25th of November. The course is organized by Medicen Paris and the Institute for Bioengineering of Catalonia (IBEC), with the collaboration of Biocat, “la Caixa” Foundation and Meditecnologia, under the framework of B·Debate. …
Nanoligent was present in the 8th edition of the BioFIT partnering event that took place this past 10-11th of December in the French city of Marseille. We showcased our project in a 5-minute pitch during the Start-up Slam and established contact with potential partners and investors. As its organizers state, BioFIT has become the meeting …
This recent 18-22th of November Nanoligent was present in the 11th Annual PEGS Europe summit, the largest European event covering all aspects of protein and antibody engineering. This year the summit broke its previous attendance records, with more than 1,300 participants and 250 scientific posters. Nanoligent presented the latest news regarding its technology and members …
Last October 29th the employers’ organization of the pharmaceutical industry in Spain, Farmaindustria, organized its latest Farma-Biotech meeting to boost pre-clinical research. The event brings together representatives of national and international pharmaceutical companies with different Spanish biotechnology companies and research groups that have innovative clinical projects. Nanoligent and six other projects were hosted because according …
This past August Nanoligent was featured in the Spanish economy newspaper elEconomista. After a brief review on the importance of technology improvements for cancer treatment, Nanoligent technology is highlighted for its selectivity, efficiency, and low toxicity. As it is explained in the article, Nanoligent drug acts only on cancer cells, based on the specific interaction …
Last June21-22th, Nanoligent was awarded the 1st prize in the Tech Transfer Competition in ONCO Emergence Forum Barcelona 2018.
This past September Nanoligent technology was featured in the health section of the Spanish national newspaper ABC. The capacity to selectivity kill metastatic stem cells, and thus, reduce the overall toxicity of the treatment is highlighted as the main strength of Nanoligent’s technology. There are currently no drugs on the market that selectively remove metastatic …
